Search

577 Result(s)
Sort by

New initiative elevates the importance of CKD testing

New initiative elevates the importance of CKD testing

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition’s unknown nature and the benefits of com
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
Accessibility Statement

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.